C. Calvet

Bristol-Myers Squibb (United States) — United States

Medicine · Health Sciences

10h-index773citations45works0.22yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(19), Lung Cancer Treatments and Mutations(18), Economic and Financial Impacts of Cancer(9), Microbial Inactivation Methods(6), Transgenic Plants and Applications(6)

Publications44 total

Repotrectinib in NTRK fusion–positive advanced solid tumors: a phase 1/2 trial
Nature Medicine·2026· 1 citedOpen Access
1988P Real-world treatment patterns and survival in patients (pts) with ROS1-positive (ROS1+) locally advanced or metastatic (LAM) non-small cell lung cancer (NSCLC) in Canada and Europe
Annals of Oncology·2025
TIGOS-LS, an open-label, randomized study of BMS-986489 vs durvalumab as consolidation therapy following chemoradiotherapy in limited-stage small-cell lung cancer.
Journal of Clinical Oncology·2025
Population-Adjusted Indirect Treatment Comparisons of Repotrectinib Among Patients with ROS1+ NSCLC
Cancers·2025Open Access
1230P Association between early endpoints and survival outcomes in neoadjuvant treatment of resectable non-small cell lung cancer (NSCLC): A multi-country retrospective study
Annals of Oncology·2024
1291P Real-world treatment and overall survival (OS) in patients (pts) with ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) in England between 2014 and 2023
Annals of Oncology·2024Open Access
PPD01.02 Repotrectinib in Patients With ROS1 Fusion-Positive (ROS1+) NSCLC: Update From the Pivotal Phase 1/2 TRIDENT-1 Trial
Journal of Thoracic Oncology·2024Open Access
Repotrectinib in tyrosine kinase inhibitor (TKI)-naïve patients (pts) with advanced <i>ROS1</i> fusion-positive (<i>ROS1+)</i> NSCLC in the phase 1/2 TRIDENT-1 trial: Clinical update, treatment beyond progression and subsequent therapies.
Journal of Clinical Oncology·2024· 1 cited
147P Population-adjusted indirect comparisons of repotrectinib and entrectinib in ROS1+ locally advanced or metastatic non-small cell lung cancer (NSCLC)
ESMO Open·2024Open Access
Abstract PR003: Repotrectinib in patients with <i>ROS1</i> fusion-positive (<i>ROS1</i>+) non-small cell lung cancer (NSCLC): Update from the pivotal phase 1/2 TRIDENT-1 trial
Molecular Cancer Therapeutics·2023· 2 cited
OA03.06 Repotrectinib in Patients with ROS1 Fusion-positive (ROS1+) NSCLC: Update from the Pivotal Phase 1/2 TRIDENT-1 Trial
Journal of Thoracic Oncology·2023· 9 citedOpen Access
Plain language summary of the CheckMate 816 study results: nivolumab plus chemotherapy given before surgery for non–small-cell lung cancer
Future Oncology·2023· 2 citedOpen Access
1348P Long-term survival and health-related quality of life with nivolumab for previously-treated advanced non-small cell lung cancer (NSCLC): A wide prospective French real-world study (EVIDENS)
Annals of Oncology·2021
PCN348 Long-Term Healthcare Resource Utilization and Costs Associated with Patients Treated with Nivolumab for Advanced Non-Small Cell Lung Cancer
Value in Health·2020
PCN350 Treatment Sequences of Patients Surviving at Least Two Years after Initiation of Nivolumab in Previously Treated Advanced Non-Small Cell Lung Cancer (aNSCLC): Contribution of Time-Sequence K-Clustering Analysis
Value in Health·2020
1276P Nivolumab treatment in advanced non-small cell lung cancer (aNSCLC): Real-world 3-year outcomes within overall and special populations (the UNIVOC study)
Annals of Oncology·2020· 1 citedOpen Access
Prise en charge des patients avec un cancer bronchique avancé et vivants deux ans après un traitement par nivolumab en deuxième ligne ou plus : intérêt des techniques de « Machine learning »
Revue d Épidémiologie et de Santé Publique·2020
1325P Long-term survival and health-related quality of life in patients treated with nivolumab for advanced non-small cell lung cancer: A wide prospective French real-world study (EVIDENS)
Annals of Oncology·2020
Nivolumab treatment in advanced non-small cell lung cancer: real-world long-term outcomes within overall and special populations (the UNIVOC study)
Therapeutic Advances in Medical Oncology·2020· 19 citedOpen Access
Nivolumab dans le cancer du poumon non à petites cellules (CBNPC) à un stade avancé : résultats d’une cohorte rétrospective nationale française (étude UNIVOC)
Revue des Maladies Respiratoires Actualités·2020
page 1 of 3Next →

Frequent Co-authors

Matteo Giaj Levra(12), R. Corre(12), V. Grumberg(12), B. Jouaneton(12), C. Chouaïd(12), Jean‐Baptiste Assié(11), François-Emery Cotté(10), R. Jolivel(8), Fabrice Barlési(8), D. Debieuvre(8), C. Raspaud(8), Denis Moro‐Sibilot(8), Clarisse Audigier-Valette(8), Bernard Asselain(8), M. Pérol(8), FE Cotté(8), A. Dixmier(7), J.B. Auliac(7), P. Bombaron(7), Lluis M. Mir(6)